Clinical Trials Logo

Filter by:
  • Not yet recruiting  
  • Page [1]
NCT ID: NCT06023277 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

Start date: April 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a proof-of-concept, single-center, non-randomized, open-label, phase 1b/2 study to evaluate the safety and efficacy of ConvitVax, a simple, low cost (of manufacture), personalized, potentially safe and effective breast cancer vaccine made of three components: autologous tumor cells homogenate obtained from 0.3 g of tumor tissue, 0.0625 mg of bacillus Calmette-Guérin Danish strain 1331 (BCG D1331), and 0.02% of formalin, for patients with metastatic breast cancer (MBC) except for brain metastases, leptomeningeal carcinomatosis, and/or spinal cord compression. The primary aim is to determine the overall safety and tolerability of ConvitVax when administered via an intradermal (id) injection as monotherapy in female patients with MBC who have failed at least one line of therapy. This study will give access to an immunotherapy, to underprivileged women with MBC, particularly in poor developing countries where patients may not have the opportunity to be treated with modern therapies or, in many cases, standard of care treatments. Breast cancer patients at Instituto de Oncología "Dr. Luis Razetti" (Oncological Institute "Dr. Luis Razetti") (IOLR) who meet the eligibility criteria will be consented and asked to have a biopsy of the primary tumor. This fragment will be divided for the preparation of each dose of the vaccine. A total of 40 patients with confirmed MBC will be treated with ConvitVax. The final volume per dose of the vaccine is 0.5 ml, with a total of 4 doses. ConvitVax will be applied via id injection with a 2-week interval between each dose. Patients will be monitored for disease recurrence and survival, for a period of 1 year after initiating the treatment.

NCT ID: NCT04329247 Not yet recruiting - Clinical trials for Carpal Tunnel Syndrome

Physical Therapy in the Treatment of Carpal Tunnel Syndrome

Start date: May 2020
Phase: N/A
Study type: Interventional

In the present investigation the pain reduction effects of a physical therapy technique will be compared to those produced by the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.

NCT ID: NCT04328805 Not yet recruiting - Clinical trials for Carpal Tunnel Syndrome

Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome.

Start date: September 2020
Phase: Phase 4
Study type: Interventional

In the present investigation the pain reduction effect of an oral ibuprofen treatment will be compared to those produced by the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.

NCT ID: NCT04285281 Not yet recruiting - Clinical trials for Carpal Tunnel Syndrome

Oral Gabapentin in the Treatment of Carpal Tunnel Syndrome

Start date: March 2020
Phase: Phase 4
Study type: Interventional

In the present investigation the pain reduction effects of Gabapentin will be compared to those produced by the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.

NCT ID: NCT04119739 Not yet recruiting - Clinical trials for Carpal Tunnel Syndrome

Pain Reduction Produced by Different Treatments in Carpal Tunnel Syndrome

Start date: April 14, 2020
Phase: Phase 4
Study type: Interventional

Pain reduction effects of the median nerve neural mobilization technique (a physiotherapy treatment) will be compared to those produced by a pharmaceutical treatment and the absence of treatment, in subjects who suffer carpal tunnel syndrome.

NCT ID: NCT03193320 Not yet recruiting - Anesthesia, General Clinical Trials

Management of Intraoperative Fluids in Ambulatory Surgery

MIFAS
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

This is a single-center prospective randomized control trial (RCT) to determine whether the continuous monitoring of the plethysmographic variability index (PVI) during low-risk surgeries, can be used to optimize the intraoperative fluid administration. Low-risk patients that attend our day surgery unit, and who will be operated under general anesthesia, will be randomized to either a liberal fluid group, a restrictive fluid group or a dynamic monitoring group (PVI-directed). The amount of fluid infused together with the time to discharge, will be assessed in each participant during the postoperative period along with additional secondary outcomes.